Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Prescripción en cuidados paliativos del cáncer: percepciones de los pacientes (DEPAL)

22 de septiembre de 2026 actualizado por: Nantes University Hospital

Prescripción de DE en cuidados paliativos del cáncer: percepciones de los pacientes: un estudio observacional mixto, prospectivo y multicéntrico

Polymedication in palliative oncology care is a real public health problem. This phenomenon has been shown to increase the risk of iatrogenesis, reduce patients' quality of life and increase healthcare costs. For many years, health policies have been developed in geriatrics to reduce polymedication through deprescription tools.

Recently, palliative care initiatives have been introduced, but without having studied the potential specificities of this population (younger, with a different care dynamic and life trajectory). It is important to better understand this population's perceptions of deprescribing in order to adapt tools/actions to make these approaches more efficient.

The primary aim of this study is to investigate patients' perceptions of deprescribing in palliative cancer care, and the secondary aim is to investigate factors that may influence patients' attitudes and beliefs about deprescribing. At the same time, we will study the psychometric properties of the rPATD (Revised Patients' Attitudes Towards Deprescribing) in this population (a standardized questionnaire validated in geriatric medicine to assess patients' perceptions of deprescription).An ancillary study will be carried out to investigate the link between patients' health literacy and their perception of deprescribing (health literacy is defined as the ability to acquire, understand and use information in ways that promote and maintain good health).

To meet our objectives, we will conduct a 3-year national, prospective, observational, multicenter study with an exploratory sequential mixed design. The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period). Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.

Thanks to the different results, we will improve our knowledge of the perception of deprescription in palliative oncology care, in order to develop approaches adapted to the specificities of our population to reduce polymedication and thus improve the quality of life of our patients and reduce the risks of iatrogenia.

Descripción general del estudio

Estado

Reclutamiento

Condiciones

Intervención / Tratamiento

Tipo de estudio

De observación

Inscripción (Estimado)

325

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

Ubicaciones de estudio

      • La Roche-sur-Yon, Francia, 85000
        • Aún no reclutando
        • CHD Vendée
        • Contacto:
      • Lyon, Francia
        • Aún no reclutando
        • Hospices Civils de Lyon
        • Contacto:
        • Investigador principal:
          • Guillaume ECONOMOS, MD
      • Nantes, Francia, 44093
        • Reclutamiento
        • CHU de Nantes
        • Contacto:
        • Investigador principal:
          • Adrien EVIN, MCU-PH
        • Sub-Investigador:
          • Yann TOUCHEFEU, PU-PH
        • Sub-Investigador:
          • André COLPAERT, PH
        • Sub-Investigador:
          • Elvire PONS-TOSTIVIN, MCU-PH
        • Sub-Investigador:
          • Gaëlle QUEREUX BAUMGARTNER, MCU-PH
      • Nantes, Francia
        • Aún no reclutando
        • USP - Maison de Nicodème
        • Contacto:
        • Investigador principal:
          • Benjamin CHARTIER, MD
      • Paris, Francia, 75005
        • Aún no reclutando
        • Hôpital Institut CURIE
        • Contacto:
        • Investigador principal:
          • Stéphanie Träger
      • Saint-Herblain, Francia, 44800
        • Aún no reclutando
        • Institut de Cancérologie de l'Ouest
        • Contacto:
        • Investigador principal:
          • BARBAROT Véronique
      • Saint-Nazaire, Francia, 44600
        • Aún no reclutando
        • CH ST Nazaire
        • Contacto:
        • Investigador principal:
          • Virginie DESSUS-CHEVREL, PH
      • Tours, Francia

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años y mayores (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Método de muestreo

Muestra no probabilística

Población de estudio

We'll be looking at major patients with "solid" cancer in a palliative situation (locally advanced or metastatic cancer, thus requiring palliative care as defined by the World Health Organization), who have at least one PIMs, followed up on an inpatient or outpatient basis, with a life expectancy estimated at less than 1 year by the doctor caring for the patient.

To identify whether a patient has at least one PIMs, we will use the STOPPFrail 2 tool . This is a tool developed in geriatrics, validated for a population with an estimated life expectancy of less than 1 year, and which is not specific to oncology. Life expectancy of less than one year will be estimated by the question surprised by the doctor caring for the patient ("Would you be surprised if your patient died within a year?") .

We will carry out a multicenter study in oncology and/or palliative care departments of hospitals located in western France.

Descripción

Inclusion Criteria:

  • Patient over 18 years of age
  • Locally advanced or metastatic solid cancer (i.e., palliative care as defined by the World Health Organization)
  • Life expectancy estimated by the physician at inclusion of less than 1 year (use of surprise question to help clinician estimate life expectancy)
  • Hospitalized or in consultation
  • With at least one PIMs (identified using STOPPfrail 2)
  • Patient not having expressed opposition to participating in the study after receiving information from the physician.

For qualitative study patients :

- Patients who have signed an authorization for the recording of their voice during the semi-structured interview for the purpose of written transcription.

Exclusion Criteria:

  • Minor
  • Major under guardianship, protected person
  • Patient unable to speak or write French
  • Patient with impaired judgment, cognitive or sensory impairment that prevents him/her from receiving informed information, answering questionnaires or participating in a study interview.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Modelos observacionales: CASE_ONLY
  • Perspectivas temporales: PROSPECTIVE

Cohortes e Intervenciones

Grupo / Cohorte
Intervención / Tratamiento
Qualitative study

The study will comprise an initial qualitative phase. Semi-directed individual interviews using a descriptive approach will be carried out (around 25 patients, over an 8-month period).

Individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis)

Quantitative study

Following analysis of the qualitative data, we will then carry out a quantitative study to determine the distribution of the different profiles within this population and the factors influencing the perception of deprescription. The self-administered questionnaires, rPATD and BMQ (medication beliefs questionnaire), potentially supplemented by other items following analysis of the qualitative data, will be administered to 300 patients (over a 12-month period).

The ancillary study will be carried out during this second phase, using a validated self-questionnaire to assess patients' level of literacy.

rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.

This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale (scale from 1 to 5, at 1 the patient completely agrees with the questionnaire's proposal, at 5 the patient strongly disagrees with the questionnaire's proposal). Following the analysis of Phase 1 "Qualitative" of the protocol, three additional questions

BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .

The Beliefs about Medicine Questionnaire (BMQ) is an 18-item self-administered questionnaire designed to explore patient perceptions of medicine. It has been validated in French and is free to use.

It comprises 10 items relating to specific beliefs about prescribed treatments:

A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief.

FCCHL (Functional, Communicative and Critical Health Literacy)/HLS14 (14-item health literacy scale) (https://reflis.fr/wp-content/uploads/2020/07/FCCHL-HLS14-Questionnaire-Litteratie-sante.pdf )

Validated French-language self-administered questionnaire and consisting of14 items with a 5-point Likert scale for assessing health literacy :

Functional literacy: basic reading and writing skills sufficient to function effectively in everyday situations Communicative or interactive literacy: more advanced cognitive and literacy skills that, combined with social skills, can be used to actively participate in everyday activities, extract information and meanings from different forms of communication, and apply new information to changing circumstances Critical literacy: more advanced cognitive skills which, combined with social skills, can be applied to the critical analysis of information and the use of that information to exercise greater control over life events and situations

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To study patients' perceptions of deprescribing in palliative cancer care.
Periodo de tiempo: at study inclusion

To describe, understand and explain patients' attitudes and beliefs concerning deprescribing by means of individual semi-structured interviews (descriptive approach methodology with reflexive thematic analysis) and secondly using the rPATD questionnaire (questionnaire for assessing patients' perceptions of their treatments and deprescribing), which can be adapted following analysis of qualitative data.

rPATD: The rPATD is a questionnaire validated and adapted in French to assess patients' perceptions of their treatments and deprescribing.

This self-administered questionnaire consists of 22 questions rated on a 5-point Likert scale

at study inclusion

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
To investigate factors that may influence patients' attitudes and beliefs regarding de-prescribing.
Periodo de tiempo: at study inclusion

Influence of gender, age, level of education, type of cancer, number of metastatic sites, Performans status score, presence of systemic cancer treatment (chemotherapy, targeted therapy, immunotherapy, hormonal therapy, etc.), follow-up by a palliative care team, and other factors. ), follow-up by a palliative care team, patient's place of care, persons in charge of treatment, number of medications, number of potentially inappropriate medications (PIMs), prognosis assessed by the referring physician, patient's level of education and beliefs about treatments in general (BMQ questionnaire) on scores from the rPATD questionnaire.

at study inclusion
To evaluate the psychometric properties of the rPATD in this population.
Periodo de tiempo: at study inclusion

Description of rPATD validation data in our population: validation of questionnaire structure, measurement of score reliability, concurrent validation with the BMQ questionnaire.

BMQ French version of the BMQ self-questionnaire, which studies patients' perceptions of medication .

A 5-point Likert-type scale was used for each item. The higher the sum of the scores obtained, the stronger the subject's belief.

at study inclusion

Otras medidas de resultado

Medida de resultado
Medida Descripción
Periodo de tiempo
ANCILLARY STUDY
Periodo de tiempo: at study inclusion

For patients who wish to do so (depending on their fatigability), we will study the link between patients' level of health literacy and their perception of deprescribing (health literacy is defined as the ability to acquire, understand and use information in ways that promote and maintain good health ).

To do this, we will assess the link between patients' level of literacy (using the FCCHL (Functional, Communicative and Critical Health Literacy) / HLS14 (14-item health literacy scale) self-questionnaire) and their perception of deprescription.

at study inclusion

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Colaboradores

Investigadores

  • Investigador principal: Adrien EVIN, Nantes University Hospital

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de febrero de 2024

Finalización primaria (Actual)

28 de febrero de 2025

Finalización del estudio (Estimado)

4 de junio de 2027

Fechas de registro del estudio

Enviado por primera vez

21 de diciembre de 2023

Primero enviado que cumplió con los criterios de control de calidad

4 de enero de 2024

Publicado por primera vez (Actual)

5 de enero de 2024

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de septiembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de septiembre de 2026

Última verificación

1 de septiembre de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • RC23_0563

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .